Prophylaxis of fungal infections in neutropenic cancer patients.
The prevention of fungal infections in granulocytopenic patients seems necessary to improve the final outcome of neoplastic patients. In particular, aspergillosis and candidiasis represent common life-threatening infections among the patients with acute hematological malignancies. Despite extensive investigations during this last decade, the optimal approaches to prevent these complications are still controversial. This situation probably reflects and stresses the numerous factors which predispose to these opportunistic fungal infections. Therefore, the effective prophylaxis of candidiasis and aspergillosis should result from the use of basic and specific approaches. General and simple measures including well trained personnel (physicians, nurses but also individuals in charge of the housekeeping, etc.), careful patient teaching of personal hygiene and control of the food intake (limited to cooked food diet), will reduce the acquisition of potential fungal pathogens. Moreover, the isolation in a laminar air flow room seems to be the optimal specific technique to prevent the colonization as well as the development of pulmonary aspergillosis. The meticulous evaluation of the respiratory sinus status as well as surveillance cultures obtained from the nose have been shown to be helpful to predict patients at high risks. Until now, there is no systemic chemoprophylaxis available to decrease the incidence of invasive aspergillosis. However, the topical application of antifungal agent using nasal spray or aerosols should be further investigated. Exogenous candidiasis such as catheter or TPN products related yeast infections can be avoided by aseptic manipulations. Endogenous candidiasis, resulting from the dissemination of the yeasts from the gastro-intestinal tract (which represents the major reservoir), are still much more difficult to prevent.(ABSTRACT TRUNCATED AT 250 WORDS)
D000380:Agranulocytosis / Q000150:complications*; D000666:Amphotericin B / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications / Q000517:prevention & control*; D002177:Candidiasis / Q000150:complications / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications*; D009761:Nystatin / Q000627:therapeutic use; D010356:Patient Isolation
D009761:Nystatin; D000666:Amphotericin B; D007654:Ketoconazole